- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | FDA defends lab test rule, as critics fear industry upheaval | ||
| Di | Lilly counts on manufacturing scale-up to unstick obesity drug supply | ||
| Di | Enlaza gets JP Morgan, Regeneron backing for covalent biologics | ||
| Di | Lilly hikes revenue forecast by $2B as GLP-1 drug sales climb | ||
| Di | Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound | ||
| Mo | FDA finalizes lab developed test rule over industry opposition | ||
| Mo | Prime gets FDA green light to begin first trial test of 'prime editing' | ||
| Mo | Deciphera sells for $2.4B, adding to upswing in biopharma M&A | ||
| Mo | AstraZeneca, Daiichi look to broaden Enhertu use again with new study data | ||
| Mo | Repertoire pivot pays dividends with Bristol Myers deal | ||
| Mo | Sustainability in pharmaceutical manufacturing: a CDMO's contribution | ||
| Mo | Systems thinking: A new paradigm for clinical trial design and operations | ||
| Fr | AbbVie tries to reassure investors on Humira biosimilar threat | ||
| Fr | Pfizer hemophilia gene therapy arrives in US to uncertain future | ||
| Do | AstraZeneca's earnings surprise investors as cancer drugs fuel growth | ||
| Do | BioMarin drops drug programs in pipeline cull | ||
| Do | Bristol Myers to cut 6% of workforce, trim drug pipeline | ||
| Do | Regeneron expands in gene editing with Mammoth deal | ||
| 24.04. | Biogen: Don't expect any big acquisitions this year | ||
| 24.04. | Moderna turns to AI to change how its employees work | ||
| 24.04. | Biogen sees 'encouraging' trends for postpartum depression drug | ||
| 24.04. | Biogen to invest more in launch of Alzheimer's drug Leqembi | ||
| 24.04. | [Podcast] Partner for Progress: Strategies for Biotech Success | ||
| 24.04. | CureVac to cut costs in restructuring | ||
| 24.04. | Endeavor pulls in $132M to back cancer, lung disease drugs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
